Dr Victoria Gahol Venida, MD | |
8700 Central Ave, Suite 203, Landover, MD 20785-4831 | |
(301) 350-0044 | |
(301) 350-8007 |
Full Name | Dr Victoria Gahol Venida |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 8700 Central Ave, Landover, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144374737 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | D0027190 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Victoria Gahol Venida, MD 8700 Central Ave, Suite 203, Landover, MD 20785-4831 Ph: (301) 350-0044 | Dr Victoria Gahol Venida, MD 8700 Central Ave, Suite 203, Landover, MD 20785-4831 Ph: (301) 350-0044 |
News Archive
Scientists at the Laboratoire éthologie Animale et Humaine (CNRS/Université de Rennes 1), working in collaboration with a neonatologist from Brest University Hospital, observed the effect of preterm babies' clothing on their behavior. Newborns placed in a sleep sack were less active and touched parts of their bodies less frequently than those dressed in a simple bodysuit.
Taking the bus is a whole lot safer than taking the car – and it's also safer for cyclists and pedestrians who take the same routes, according to a new study led by the Université de Montréal Public Health Research Institute (IRSPUM).
AIDS Healthcare Foundation (AHF) has urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS.
Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.
› Verified 8 days ago